Ligand Pharmaceuticals Incorporated (LGND:NASDAQ) closed at $306.20 on November 6, 2026, up 2.41% on the day. The stock trades 6.3% below its 52-week high of $326.63 and 74.1% above its 52-week low of $175.89. Over the past year, it gained 51.2%. Ligand Pharmaceuticals Incorporated is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 6, 2025, LGND closed higher on 131 days (52%). Its best day was November 6, 2025 (+9.37%) and its worst was May 7, 2026 (-9.55%). It never moved 10% or more in a single session.
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, oncology, allergy, anti-coagulant, depression, sun damage, blood disorders, and diabete...
Find more stocks like LGND with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.